Ardea Biosciences Presents Inflammation Program Data for Arthritis and Gout at 2008 Annual European Congress of Rh...(recurrently conducting a Phase 1 proof-o...)

Date:6/11/2008

re currently conducting a Phase 1 proof-of-concept trial in healthy volunteers, which we expect to complete in the second half of this year," said Barry D. Quart, PharmD, Ardea Biosciences' President and CEO. "In addition, we are on track to begin two gout trials, a Phase 1 trial with RDEA594 in the second half of this year and a Phase 2 proof-of-concept trial with RDEA594's prodrug, RDEA806, in the third quarter of this year."

Analysis of two Phase 1 healthy volunteer studies of the Company's lead NNRTI candidate, RDEA806, revealed statistically significant reduction of serum uric acid (sUA) compared to placebo. In order to further understand the mechanism responsible for the sUA lowering effect, extensive experiments were conducted. Based on these studies, RDEA594 was identified as a major metabolite of RDEA806 in both humans and animals. RDEA594 exhibits a concentration-dependent inhibitory effect on the URAT1-mediated uptake of uric acid ex vivo and increases uric acid excretion in animal models. These findings suggest that RDEA594's effect on both the uptake and excretion of uric acid is responsible for essentially all of the uric acid lowering effects seen with its prodrug, RDEA806.

About RDEA119

RDEA119, a non-ATP competitive, highly-selective MEK inhibitor for the treatment of inflammatory diseases and cancer, is the Company's lead compound from its MEK inhibitor research and development program. RDEA119 has shown potential as a potent inhibitor of MEK, which is believed to play an important role in inflammation, as well as cancer cell proliferation, apoptosis and metastasis. Preclinical and clinical results suggest that RDEA119 has favorable properties, including oral dosing, excellent selectivity and limited retention in the brain, which, in turn, may result in a reduced risk of central nervous system (CNS) side effects. The Company is also investigating a second generation MEK inhibitor, RDEA436, for potential use in inflammatory dise
'/>"/>

SOURCE Ardea Biosciences, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at Digestive Disease Week 2008
2. Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resistant Viruses
3. Ardea to Present Data on HIV Non-Nucleoside Reverse Transcriptase Inhibitor and Two MEK Inhibitors at Upcoming Medical Conferences
4. Ardea to Present at Cowen and Companys 28th Annual Health Care Conference
5. Ardea Biosciences to Move Headquarters and R&D Laboratories to San Diego
6. Ardea Biosciences Establishes Scientific Advisory Board for Inflammation Program
7. Ardea Biosciences to Present at Roth Capital Partners 20th Annual OC Growth Stock Conference
8. Ardea Biosciences Establishes Scientific Advisory Board for HIV Program
9. Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections
10. Ardea Biosciences Announces $40 Million Private Placement
11. Ardea Biosciences to Participate in RBC Capital Markets 2007 Healthcare Conference